Bizarre Patents
A self defense weapon formed as a memo pad and which is easily held by a person's fingers, therefore making it possible to provide protection from a mugger and also to quickly and easily write a record or a message without failure of missing or forgetting significant information under a stressful situation.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129819 | GEL COMPOSITIONS FOR ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS The present invention provides a pharmaceutical composition in the form of a water-based gel comprising: at least one pharmaceutically active compound; at least one gelling agent; a solubilising agent; and water, wherein said composition is free or substantially free of... | 05/24/2012 |
| 20120128733 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE DRUGS, CONTRACEPTIVE KITS COMPRISING ACTIVE DRUGS, AND METHODS OF ADMINISTERING THE SAME The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may ... | 05/24/2012 |
| 20120082714 | TRANSDERMAL THERAPEUTIC SYSTEM WITH CRYSTALLIZATION-INHIBITING PROTECTIVE FILM (RELEASE LINER) The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-... | 04/05/2012 |
| 20120071449 | PHARMACEUTICAL COMPOSITION FOR INHALATION The present invention relates to a pharmaceutical composition for inhalation. The invention is further directed to a method for setting the performance characteristics of such a pharmaceutical composition and the use of such a composition in the treatment of asthma, COP... | 03/22/2012 |
| 20120046254 | DISPERSION OF PHYTOSTEROLS The invention relates to a method for the production of highly stable aqueous dispersions of phytosterols, phytostanols and derivatives thereof, which allows the use of a wide range of emulsifiers in relatively small concentrations in relation to the phytosterols and wh... | 02/23/2012 |
| 20120046518 | Estrus Synchronization Preparations & Effective CIDR-Less Protocols An injectable preparation of estrogenic and progestrogenic hormonal compounds in an anhydrous excipient injected to synchronize estrus in non-menstruating placental female animals, and a five to nine day protocol to apply the unique preparation to achieve estrus synchro... | 02/23/2012 |
| 20120041524 | Compositions for Providing Vitamin D Year Round and Uses Thereof Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.... | 02/16/2012 |
| 20120035144 | MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID, AND AN ANTIFUNGAL AGENT, AND A PROCESS TO MAKE IT. The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisati... | 02/09/2012 |
| 20120028936 | ORAL CONTRACEPTION WITH TRIMEGESTONE The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the da... | 02/02/2012 |
| 20120028935 | Therapeutic Gestagens for the Treatment of Premenstrual Dysphoric Disorder A method of treating premenstrual dysphoric disorders comprising administering to a patient in need of such treatment daily from day 1 to day 24 3 mg of drospirenone and 0.02 mg of ethinylestradiol.... | 02/02/2012 |
| 20120021041 | TRANSDERMAL DELIVERY Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.... | 01/26/2012 |
| 20120015917 | Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy The present invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen. The progestogen is levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, trimegestone, dienogest, precursors thereof and... | 01/19/2012 |
| 20120014915 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor activ... | 01/19/2012 |
| 20120004169 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions conta... | 01/05/2012 |
| 20110319370 | Combination Hormone Therapy for the Eye An ophthalmic instillation composition which contains melatonin and at least one other hormone, typically an estrogen but also possibly testosterone or another aromatasable androgen. The instillation is designed to reduce or eliminate cataracts in men or women to which ... | 12/29/2011 |
| 20110319369 | COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17α-hydroxylase/C17,20-lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently u... | 12/29/2011 |
| 20110312916 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS Prodrugs of C-17-heterocyclic-steroidal drugs providing improved oral bioavailability and pharmacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (AR), and are useful ... | 12/22/2011 |
| 20110288059 | NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE THEREFOR Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for amelior... | 11/24/2011 |
| 20110281830 | NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE AND STEROIDS The invention discloses a dermaceutical cream containing steroids and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under... | 11/17/2011 |
| 20110281831 | NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, ANTIFUNGALS AND STEROIDS The invention discloses a dermaceutical cream containing antifungal agents, steroids and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into... | 11/17/2011 |
| 20110275601 | VERY LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceuti... | 11/10/2011 |
| 20110269725 | NOVEL ESTROGENIC COMPOUNDS Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from... | 11/03/2011 |
| 20110263546 | Polyhydroxylated Bile Acids for Treatment of Biliary Disorders The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow.... | 10/27/2011 |
| 20110256210 | Transdermal Delivery Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.... | 10/20/2011 |
| 20110256211 | Transdermal Delivery Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.... | 10/20/2011 |
| 20110251163 | Transdermal Delivery Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.... | 10/13/2011 |
| 20110245211 | METHOD FOR CONTRACEPTION The invention relates to a method of contraception, which method comprises administering to a woman in need thereof an emergency contraception during one or two days, followed by a prolonged low dosage contraceptive treatment until next menstrual period.... | 10/06/2011 |
| 20110244059 | INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR The present invention relates to methods of mitigating, preventing or treating weight gain or obesity in patients by administering one or more autophagy inhibitors, thereby, preventing the differentiation process of pre-adipocyte cells into a mature adipocytes. Specific... | 10/06/2011 |
| 20110230453 | Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics The present invention provides a method for determining the gender of a fetus by assaying the sex hormones, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the maternal urine or other body fluid. The metho... | 09/22/2011 |
| 20110212931 | ANTIOXIDANT Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected ... | 09/01/2011 |
| 20110201579 | Method of Improving the Overall Health of a Patient by Application of Pregnenolone A method is described herein for improving the overall health of a patient by providing subcutaneous pellets containing pregnenolone to at least one part of the body of the patient. In another embodiment, pregnenolone is mixed with DHEA into a cream and the resulting pr... | 08/18/2011 |
| 20110195031 | METHODS FOR THE USE OF PROGESTOGEN AS A GLUCOCORTICOID SENSITIZER Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity... | 08/11/2011 |
| 20110195942 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3 -one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7α,... | 08/11/2011 |
| 20110189293 | THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS A method for treating an immunoinflammatory disorder in a subject in need thereof, said method comprising administering to said subject a unit dosage form comprising dipyridamole coated onto acid beads and formulated for controlled release. The method further including ... | 08/04/2011 |
| 20110172197 | Dosace Form For Hormonal Contraceptive A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily ... | 07/14/2011 |
| 20110160167 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process... | 06/30/2011 |
| 20110160169 | METHOD FOR PRODUCING HIGH SAPOGENIN CONTENT COMPOSITION A method for producing a high sapogenin content composition, including: allowing a strong acid aqueous solution having a concentration of 0.01 mol/L to 4 mol/L to act on a saponin-containing plant, so as to perform hydrolysis treatment; neutralizing a liquid obtained by... | 06/30/2011 |
| 20110160168 | MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a t... | 06/30/2011 |
| 20110151003 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery p... | 06/23/2011 |
| 20110144016 | Methods and Compositions for Treating Cancer Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5,16... | 06/16/2011 |
